DYN240920C25000
- 7.50
- 0.000.00%
Dyne Therapeutics Newsroom
Dyne Therapeutics(DYN.US) Officer Sells US$4.05 Million in Common Stock
$Dyne Therapeutics(DYN.US)$ Officer Scalzo Richard William sold 126.07K shares of common stock on Sep 6, 2024 at an average price of $32.15 for a total value of $4.05 million.Source: Announcement
Form 144 | Dyne Therapeutics(DYN.US) Officer Proposes to Sell 4.24 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 6, $Dyne Therapeutics(DYN.US)$ Officer Scalzo Richard William intends to sell 126.07K shares of its common stock on Aug 19, with a total market value of approximately $4.24
CEO, President & Director of Dyne Therapeutics John Cox Buys 640% More Shares
Form 144 | Dyne Therapeutics(DYN.US) Officer Proposes to Sell 5.61 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 5, $Dyne Therapeutics(DYN.US)$ Officer McNeill Jonathan intends to sell 166.77K shares of its common stock on Sep 5, with a total market value of approximately $5.61
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
H.C. Wainwright analyst Andrew Fein maintains $Dyne Therapeutics(DYN.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 46.2%
Dyne Therapeutics Insider Bought Shares Worth $1,057,216, According to a Recent SEC Filing
A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $50 to $55
On Sep 04, major Wall Street analysts update their ratings for $Dyne Therapeutics(DYN.US)$, with price targets ranging from $50 to $55.Morgan Stanley analyst Michael Ulz maintains with a buy rating,
Buy Rating Affirmed Amidst Dose Adjustments and Promising Trial Results for Dyne Therapeutics
Small U.S. Stocks Decrease; Dyne Therapeutics Takes Biggest Hit
Oppenheimer Reiterates Outperform on Dyne Therapeutics, Maintains $55 Price Target
Dyne Therapeutics Analyst Ratings
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
Dyne Therapeutics (DYN) Receives a Buy From Stifel Nicolaus
Vaxcyte PCVX Phase 1/2 Data; Dyne Therapeutics DYN Phase 1/2 DMD Results
Express News | Dyne Therapeutics Shares Down 29.5% Premarket After Co Reports Early-Mid-Stage Study Data for Muscular Disorder Drug
Express News | Dyne Therapeutics Inc - Dyne-251 Demonstrates Favorable Safety Profile
Press Release: Dyne Therapeutics Announces Key Leadership Appointments
Express News | Dyne Therapeutics Inc - Initiating Registrational Cohorts With Update on Path to Registration by Year-End 2024
Express News | Dyne Therapeutics Inc - to Provide Registration Update by Year-End
Dyne Therapeutics Announces New Clinical Data From Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts